Dr. Yosef Landesman

Yosef (Yossi) Landesman is a veteran biotech and pharmaceutical executive with over two decades of experience spanning drug discovery, preclinical development, and regulatory strategy.

He played pivotal scientific roles in the development of FDA-approved therapies XPOVIO® (selinexor) and ONPATTRO® (patisiran).

His therapeutic focus includes oncology, neurology, immunology, and rare diseases, with extensive expertise in RNA-based modalities such as siRNA, tRNA, and RNAi.
Yossi has successfully led translational and DMPK strategies, helping programs move efficiently from discovery to IND submission.

He contributes to clinical trial oversight as a member of multiple Data and Safety Monitoring Boards (DSMBs) for oncology studies.

He brings strategic insight into biomarker development, preclinical pharmacology, and integration of early-stage data into clinical planning.
At SBH Sciences, Yossi consults on scientific direction and translational research